Safety and efficacy of single‐agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open‐label, phase 2 study. (June 2017) - Collins, G.P.; Noy, A.; de Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C.; Morschhauser, F.; Ma, S.; Coleman, M.; Peles, S.; Smith, S.; Barrientos, J.; et al.